William F. Daniel - 10 May 2021 Form 4 Insider Report for Horizon Therapeutics Public Ltd Co

Role
Director
Signature
/s/ Miles McHugh, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
10 May 2021
Net transactions value
-$1,477,275
Form type
4
Filing time
12 May 2021, 17:01:05 UTC
Next filing
02 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HZNP Common Stock Options Exercise $254,000 +20,000 $12.70* 20,000 10 May 2021 Direct
transaction HZNP Common Stock Sale $1,716,831 -19,834 -99% $86.56 166 10 May 2021 Direct F1
transaction HZNP Common Stock Sale $14,444 -166 -100% $87.01 0 10 May 2021 Direct
holding HZNP Common Stock 74,467 10 May 2021 By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HZNP Stock Option (Right to Buy) Options Exercise $0 +20,000 $0.000000 13,286 10 May 2021 Ordinary Shares 20,000 $12.70 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.00 to $87.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The stock option vested in 36 equal monthly installments following the date of grant.